Latest Period
Q2 2026
Security Snapshot
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) Institutional Ownership
CUSIP: 03753U106
13F Institutional Holders and Ownership History from Q4 2017 to Q2 2026
Institutions Reporting
1
Shares (Excl. Options)
248
Price
$41.03
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- APLS
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 248
- Total 13F value
- $10,175
- Portfolio coverage rank
- 0%
- Share change
- -135,901,314
- Value change
- -$5,455,548,920
- Number of holders
- 1
- Shares outstanding
- 127,672,507
- SEC-reported price per share
- $41.03
- Insider filing price
- $41.03
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- APLS - Apellis Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 03753U106.
- 1 institution reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 315 to 1 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $5,518,735,195 to $10,175.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 1 institution filings for Q2 2026.
Security key
03753U106
Latest holder period
Q2 2026
13F holders
1
13D/G owners
6
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03753U106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
APLS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 10% | +120% | $332,289,194 | +$191,653,065 | 13,228,073 | +136% | BlackRock, Inc. | 31 Jan 2026 |
| STATE STREET CORP | 5.4% | $278,524,311 | 6,845,031 | STATE STREET CORPORATION | 31 Mar 2026 | |||
| Deep Track Capital, LP | 3.6% | -34% | $184,422,298 | -$100,407,702 | 4,532,374 | -35% | Deep Track Capital, LP | 31 Mar 2026 |
| RTW INVESTMENTS, LP | 2.9% | -53% | $149,944,481 | -$162,016,146 | 3,685,045 | -52% | RTW Investments, LP | 31 Mar 2026 |
| EcoR1 Capital, LLC | 2.7% | $78,009,140 | 3,447,156 | EcoR1 Capital, LLC | 30 Sep 2025 | |||
| WELLINGTON MANAGEMENT GROUP LLP | 0.2% | -97% | $10,042,791 | -$543,140,340 | 249,635 | -98% | Wellington Management Group LLP | 31 Mar 2026 |
As of 30 Jun 2026, 1 institutional investors reported holding 248 shares of Apellis Pharmaceuticals, Inc. - Common Stock (APLS). This represents 0% of the company’s total 127,672,507 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
35
Latest
Q2 2026
Rows shown
1-25 of 35
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 248 | $10,175 | -$5,455,548,920 | $41.03 | 1 |
| 2026 Q1 | 137,471,926 | $5,518,735,195 | +$611,506,729 | $40.23 | 315 |
| 2025 Q4 | 126,342,544 | $3,169,570,181 | +$136,391,907 | $25.12 | 277 |
| 2025 Q3 | 122,308,038 | $2,770,590,650 | -$153,668,109 | $22.63 | 272 |
| 2025 Q2 | 131,608,288 | $2,279,077,423 | +$66,148,357 | $17.31 | 246 |
| 2025 Q1 | 126,465,800 | $2,767,959,579 | -$78,248,319 | $21.87 | 252 |
| 2024 Q4 | 126,723,891 | $4,044,170,293 | +$224,206,429 | $31.91 | 259 |
| 2024 Q3 | 118,165,642 | $3,408,098,233 | -$32,772,311 | $28.84 | 261 |
| 2024 Q2 | 115,428,997 | $4,426,484,074 | -$4,063,210 | $38.36 | 259 |
| 2024 Q1 | 113,103,917 | $6,646,510,438 | -$27,789,991 | $58.78 | 296 |
| 2023 Q4 | 113,568,311 | $6,800,298,011 | +$75,955,536 | $59.86 | 278 |
| 2023 Q3 | 113,630,426 | $4,326,001,749 | -$249,890,323 | $38.04 | 250 |
| 2023 Q2 | 106,464,737 | $9,698,740,546 | -$322,780,479 | $91.10 | 311 |
| 2023 Q1 | 110,363,167 | $7,278,027,538 | +$671,099,429 | $65.96 | 277 |
| 2022 Q4 | 100,652,525 | $5,202,853,976 | +$66,260,972 | $51.71 | 239 |
| 2022 Q3 | 97,643,165 | $6,665,378,163 | +$32,228,664 | $68.30 | 245 |
| 2022 Q2 | 91,648,969 | $4,144,516,571 | +$31,626,482 | $45.22 | 205 |
| 2022 Q1 | 90,940,512 | $4,620,842,334 | +$520,061,489 | $50.81 | 206 |
| 2021 Q4 | 81,021,271 | $3,829,991,538 | +$612,446,955 | $47.28 | 183 |
| 2021 Q3 | 69,511,931 | $2,291,947,609 | -$95,194,645 | $32.96 | 174 |
| 2021 Q2 | 64,601,991 | $4,083,171,314 | +$13,404,010 | $63.20 | 201 |
| 2021 Q1 | 63,358,839 | $2,718,377,161 | +$19,912,136 | $42.91 | 168 |
| 2020 Q4 | 63,890,305 | $3,654,164,157 | -$7,921,158 | $57.20 | 165 |
| 2020 Q3 | 62,139,394 | $1,874,756,231 | +$24,663,304 | $30.17 | 143 |
| 2020 Q2 | 61,184,997 | $1,997,919,282 | +$197,934,910 | $32.66 | 141 |